BNT162b2 mRNA COVID-19 Vaccine: First Approval-Reference-Cited by-同舟云学术

BNT162b2 mRNA COVID-19 Vaccine: First Approval

Published:2021-03 Issue:4 Volume:81 Page:495-501
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Lamb Yvette N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-021-01480-7.pdf

Reference31 articles.

1. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27.

2. Rego GNA, Nucci MP, Alves AH, et al. Current clinical trials protocols and the global effort for immunization against SARS-CoV-2. Vaccines. 2020;8(3):1–44.

3. Abbasi J. COVID-19 and mRNA vaccines - first large test for a new approach. JAMA. 2020;324(12):1125–7.

4. European Medicines Agency. Covid-19 mRNA vaccine (Comirnaty): EU summary of product characteristics. 2020. http://ec.europa.eu. Accessed 11 Feb 2021.

5. BioNTech. Aiming to address the global coronavirus pandemic: Project Lightspeed. 2020. https://biontech.de. Accessed 11 Feb 2021.

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery;International Journal of Pharmaceutics: X;2024-12

2. COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review;Vaccine: X;2024-10

3. A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals;Archives of Toxicology;2024-09-03

4. Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77;International Journal of Biological Macromolecules;2024-09

5. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches;Biochemistry and Biophysics Reports;2024-09